AI Robotics in Medicine

AI in healthcare is moving from promise to commercialization: Butterfly’s ultrasound-on-chip platform anchors a Midjourney licensing and co-development deal worth up to $74 million over five years, alongside $102. 9 million in revenue ($81.

8 million U.S., $21. 2 million international) and new Brazil and neuroimaging partnerships pointing to real-world use.

Pfizer and Medtronic reinforce the trend—Pfizer pursuing AI to speed antibody and drug design even as it faces expected revenue/earnings declines and a >7% dividend not covered by earnings or free cash flow, while Medtronic builds AI-powered surgical tools.

Watch whether these AI bets deliver measurable cost savings under hospital budget pressure and how financial constraints shape adoption timelines.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

1. Butterfly's $74m Midjourney pact spotlights AI moves at Pfizer and Medtronic

AI in healthcare is advancing as hospitals face pressure to do more with less and software aims to cut costs. Against that backdrop, the article highlights Butterfly Network, Pfizer, and Medtronic as AI-exposed healthcare plays.

The standout move: Butterfly’s ultrasound-on-chip tech underpins a multi-year licensing and co-development deal with Midjourney worth up to $74 million over five years, alongside $102. 9 million in revenue split between $81.

8 million in the U.S. and $21. 2 million internationally.

Pfizer is leaning on AI collaborations to speed antibody and drug design while reporting about $63. 2 billion in revenue, with $37.

4 billion from the U.S., $9. 4 billion from emerging markets, and $16.

4 billion from other developed markets. The company faces expected revenue and earnings declines and a dividend yield above 7% not covered by earnings or free cash flow.

Medtronic’s portfolio includes surgical robotics and AI-powered surgical video tools, while Butterfly notes recent Brazil deals and neuroimaging partnerships indicating real-world use.

Key facts:

- Butterfly inked a licensing and co-development deal with Midjourney worth up to $74m over five years.

- Butterfly revenue totals about $102.9m: $81.8m U.S., $21.2m international.

- Butterfly sells iQ+ and iQ3 handheld ultrasound with AI tools Compass AI, ScanLab.

- Recent Brazil deals and neuroimaging partnerships show Butterfly’s real-world deployments.

- Pfizer revenue about $63.2b; $37.4b U.S., $9.4b emerging, $16.4b other developed.

Why it matters: Hospitals are under cost pressure, and AI tools promise efficiency gains across imaging, surgery, and drug R&D.

Butterfly’s Midjourney deal signals tangible monetization of ultrasound-on-chip beyond device sales, a potential lever for scaling bedside imaging where staffing and budgets are tight.

For pharma, Pfizer’s AI push targets faster molecule and antibody design, but it must offset expected revenue and earnings declines and a stretched dividend.

For devices, Medtronic’s AI-assisted surgery stack underlines how robotics and computer vision are becoming standard in operating rooms.

Watch whether these AI initiatives translate into sustainable revenue growth and improved profitability trajectories highlighted in the piece.

Simplywall